lds1 as a potential target in sclc
Published 2 years ago • 95 plays • Length 3:46Download video MP4
Download video MP3
Similar videos
-
0:55
the potential of targeted and immune therapies in sclc
-
2:33
concurrent immunotherapy in sclc
-
3:33
molecular drivers and therapeutic targets for neuroendocrine transformation in lung cancer
-
3:02
neoadjuvant and adjuvant immunotherapy in non-small cell lung cancer
-
2:47
update from a phase 1 study of amg 757 in sclc
-
0:50
kras g12c emerges as new potential target in non-small cell lung cancer
-
7:14
safety and efficacy of single agent rovalpituzumab tesirine in small cell lung cancer (sclc)
-
8:14
approaching non-driver stage iv nsclc
-
1:36
met as a clinical target in lung cancer
-
51:59
facilitating progress in the treatment of sclc
-
5:53
targeted therapy in non-small cell lung cancer
-
7:03
uses of radiotherapy for small cell lung cancer
-
4:18
impower110: atezolizumab vs chemo in pd-l1–selected nsclc
-
3:31
ret as a target in lung cancer
-
8:25
first ‘targeted’ treatment for small cell lung cancer shows promise
-
2:11
combination of wee1 inhibition and immunotherapy provides promising preclinical data for sclc
-
5:07
presentation of a 73-year-old woman with stage iv sclc
-
1:56
rovalpituzumab in small cell lung cancer (sclc)
-
1:20
dr. charles rudin: immunotherapy for small cell lung cancer